Expanding global access to oncology trials: mCODE-aligned AI for inclusive patient matching across literacy and resource settings.

Y Yan Leyfman (5NewYork-Presbyterian Hospital, Hematology, New York, United States) A Arturo Loaiza-Bonilla (3St. Luke's Cancer Center, Oncology Hematology, Easton, United States) V Viviana Cortiana (University of Bologna, Bologna, Italy) E Ertugrul Tuysuz (Massive Bio, New York, NY) S Selin Kurnaz (Massive Bio, Boca Raton, FL) O Oz Huner (Massive Bio, New York, NY) J Juan PN Menza (Massive Bio, New York, NY) S Serkan Yerdan (Massive Bio, New York, NY) C Cagatay Cagatay (Massive Bio, New York, NY)

Abstract

18 Background: Clinical trial enrollment remains a global bottleneck in oncology. Despite therapeutic advances, only a minority of eligible patients enroll, largely due to fragmented electronic health records (EHRs), manual chart abstraction, and health literacy barriers. These limitations disproportionately affect patients in under-resourced settings and globally diverse populations. We evaluated an AI-powered platform designed to automatically extract oncology data from EHRs and structure them according to the Minimal Common Oncology Data Elements (mCODE) framework to enable scalable, interoperable trial matching. Methods: A fine-tuned GPT-4o model was developed to process structured and unstructured oncology EHR data. In a validation cohort of 102 patients (randomly sampled from a 3,800-patient oncology database), the system extracted tumor type, stage, disease extent, relapse status, resectability, and genomic biomarkers. Variables were mapped to mCODE 3.0 profiles (Cancer Disease Status, Tumor Characteristics, Genomics) and validated against expert chart review. Primary endpoints were accuracy (concordance) and completeness. Secondary endpoints evaluated interoperability and readiness for downstream clinical trial matching. Results: AI achieved high accuracy for tumor type (98%), extent of disease (90%), and stage (86%). Genomic extraction demonstrated 78% accuracy, reliably identifying common alterations including BRCA1/2 and TP53. Lower concordance in relapse status (77%) and resectability (69%) reflected documentation variability in free-text notes. All outputs were successfully structured within mCODE schemas. Compared with manual abstraction, AI reduced processing time substantially while maintaining clinical validity. Standardized outputs enabled seamless integration into multi-lingual, plain-language trial matching interfaces. Conclusions: AI-driven oncology data standardization aligned with mCODE enables scalable, real-time clinical trial matching across diverse health systems. By embedding interoperability at the data-extraction stage, this framework directly addresses structural and literacy-based barriers to trial access. These findings support the feasibility of AI-assisted infrastructure to democratize precision oncology research beyond geographic and language constraints.

Article Details

Volume / Issue Vol. 44, Issue 19_suppl
Published July 01, 2026
Pages 18-18
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (9)

Y

Yan Leyfman

5NewYork-Presbyterian Hospital, Hematology, New York, United States

A

Arturo Loaiza-Bonilla

3St. Luke's Cancer Center, Oncology Hematology, Easton, United States

V

Viviana Cortiana

University of Bologna, Bologna, Italy

E

Ertugrul Tuysuz

Massive Bio, New York, NY

S

Selin Kurnaz

Massive Bio, Boca Raton, FL

O

Oz Huner

Massive Bio, New York, NY

J

Juan PN Menza

Massive Bio, New York, NY

S

Serkan Yerdan

Massive Bio, New York, NY

C

Cagatay Cagatay

Massive Bio, New York, NY